Semaglutide Food Reward Study: Why Calorie Reduction Lasted 60 Weeks

Bottom line: A 60-week randomized controlled trial found that <a href="https://glp1place.com/tools/compound/semaglutide/”>semaglutide 2.4 mg continued to reduce measured calorie intake in adults with overweight or obesity at weeks 20, 40, and 60. Some subjective effects—including appetite suppression, hunger, and food preoccupation—were strongest earlier and were no longer significantly different from placebo by weeks 40 or 60. The peer-reviewed semaglutide food reward study suggests that long-term weight maintenance may depend less on continuously feeling dramatically less hungry and more on persistent changes in food intake.

GLP1Place Research Team

Public discussions of <a href="https://glp1place.com/tools/compound/glp-1/”>GLP-1 medicines often reduce their effects to one phrase: “they suppress appetite.” That description is directionally correct but incomplete. Appetite is not a single biological measure. It includes hunger, fullness, expected food consumption, food preoccupation, the rewarding value of food, and actual energy intake. These measures do not necessarily change together or remain changed for the same length of time.

The new trial, published in the American Journal of Clinical Nutrition in August 2026, provides a detailed long-term look at these differences. It was not designed to prove that semaglutide works through one pathway alone. Instead, it repeatedly measured eating behavior under standardized conditions and compared semaglutide with placebo over 60 weeks.

What the semaglutide food reward study tested

The study randomized 120 adults with overweight or obesity in a 3:2 ratio to semaglutide 2.4 mg or placebo. It was double-blind and placebo-controlled, meaning participants and investigators were not supposed to know each participant’s treatment assignment during the blinded period.

Researchers conducted laboratory assessments at baseline and at weeks 20, 40, and 60. The protocol examined several related but separate outcomes:

• Appetite while fasting.
• Appetite during the four hours after a standardized breakfast.
• Energy intake during an ad libitum lunch.
• Recent hunger.
• Food preoccupation, or how much mental attention food occupied during the preceding week.
• Food-reward responsiveness, measured in part with the Power of Food Scale.

The study also has limits. The sample included 120 adults, the lunch assessment took place in a research environment, and several outcomes relied on self-reported or questionnaire-based measures. A controlled meal test can detect changes in energy intake, but it does not reproduce every eating decision made in everyday life.

The main result: calorie intake stayed lower through week 60

The most durable result was measured energy intake rather than a subjective appetite score.

Compared with placebo, the semaglutide group consumed significantly fewer calories during the ad libitum lunch at all three post-baseline assessments. The reported mean differences in change from baseline were approximately:

These were mean differences, not guarantees for every participant. The findings also should not be converted into a personal calorie target or an individual weight-loss prediction. Their value is that the same general pattern appeared repeatedly during a standardized meal assessment.

The researchers concluded that semaglutide continued to help participants consume fewer calories at weeks 20, 40, and 60. This supports the idea that changes in energy intake can remain measurable over time even when a person no longer describes intense appetite suppression.

Why persistent calorie reduction is different from feeling less hungry

People often use hunger as a stand-in for everything related to eating. This trial shows why that can be misleading.

A person may no longer feel the same dramatic fullness or appetite suppression seen during the first months yet still eat less overall. Food may be less noticeable during decisions, portions may become smaller, high-reward foods may be less compelling, or a person may stop eating sooner without describing the experience as “suppressed appetite.”

This interpretation reflects the overall pattern; it does not prove one hidden mechanism. The study measured actual intake and several psychological constructs, but it did not map every neural, hormonal, gastrointestinal, and behavioral process contributing to the result.

Appetite suppression was strongest earlier in treatment

At week 20, semaglutide-treated participants showed greater appetite suppression after the standardized breakfast than the placebo group. The study also reported greater reductions in past-week hunger and food preoccupation at that point.

Those differences were less clear at later visits. The groups did not differ significantly in the measured appetite outcomes at weeks 40 or 60. This does not mean semaglutide stopped affecting eating behavior. It means the specific subjective appetite measures used in the study were no longer statistically distinct between treatment groups at those later time points.

That distinction matters. A nonsignificant difference is not evidence that the groups were identical in every respect. It means the study did not detect a statistically reliable difference for that outcome at that time point using its analysis.

Several explanations are possible:

• Participants may adapt to the subjective sensations associated with treatment.
• Placebo participants may also change eating behavior during repeated study visits.
• Appetite ratings may be noisier than direct meal-intake measurements.
• Weight loss itself may alter hunger and satiety signals in both directions.
• The sample may not have been large enough to detect smaller late-stage differences.

The most defensible conclusion is that early subjective appetite effects were not the only factor associated with the longer-term reduction in measured intake.

What changed in food reward?

The study also examined the rewarding value of food. Food reward is broader than hunger. It can include how pleasurable food seems, how strongly food cues attract attention, and how much motivational value a person assigns to eating.

Semaglutide produced greater reductions in responsiveness to the rewarding value of food at weeks 20 and 40. The reported group differences were approximately -0.4 at week 20 and -0.6 at week 40 on the study’s measure. The abstract did not report a statistically significant difference for this outcome at week 60.

These findings are consistent with a model in which GLP-1 receptor agonism influences both homeostatic eating signals and reward-related eating behavior. Homeostatic signals relate to the body’s energy needs, while reward-related processes involve the motivational pull of food even when immediate energy needs are not high.

However, the trial does not establish that semaglutide “turns off” the brain’s reward system. The Power of Food Scale and related assessments are behavioral and psychological instruments. They can detect changes in food-related responsiveness, but they are not direct measurements of neuronal activity.

Readers looking for the broader biology can review GLP1Place’s existing discussion of the gut-brain axis and GLP-1 signaling. The new study adds behavioral evidence to that field; it does not replace neuroimaging, pharmacology, or mechanistic research.

Why the 60-week follow-up matters

Many appetite studies are short. They can show what happens early in treatment, but they cannot show whether an effect persists after months of exposure and weight change.

The 60-week design addresses a practical research question: does the eating behavior associated with semaglutide remain different after the initial period of weight loss? In this study, the answer was yes for measured calorie intake. The answer was more mixed for self-reported appetite and food-reward outcomes.

This pattern helps show why long-term weight-management research cannot rely on one subjective question such as “How hungry do you feel?” Weight regulation is dynamic. The body, eating environment, treatment exposure, learned behavior, and expectations can all change during a year of therapy.

It may also explain why some people report that semaglutide feels less noticeable over time without necessarily returning to their previous eating pattern. A weaker sensation of appetite suppression does not automatically mean the medicine has lost every effect on intake. Conversely, the study does not prove that every person will maintain lower intake or weight indefinitely.

How this study fits with existing GLP-1 research

The findings extend rather than overturn the established clinical picture of semaglutide.

Earlier research has shown that semaglutide can reduce body weight and influence appetite, food intake, eating control, and food preferences. The distinctive contribution of this 2026 trial is its repeated comparison of several behavioral outcomes over 60 weeks.

GLP1Place’s existing semaglutide clinical-data overview covers the broader STEP and SUSTAIN evidence base. This study is best read as a focused behavioral-mechanism article, not as a replacement for those larger efficacy and safety trials.

The trial also should not be used to claim that semaglutide works only by reducing food reward. Semaglutide has effects across multiple physiological systems, including appetite regulation, gastrointestinal signaling, glucose regulation, gastric emptying, and central nervous system pathways. The contribution of each pathway may vary by person, dose, treatment duration, and clinical context.

Industry Impact

The study has implications for how obesity medicines are developed and evaluated.

First, future trials may need to track actual food intake and eating behavior alongside body weight. Weight is an important endpoint, but it is the final result of multiple interacting processes. A medicine that changes meal size, food reward, hunger, or eating frequency may produce meaningful effects even when those measures do not all change in parallel.

Second, the findings support longer behavioral follow-up for next-generation incretin medicines. A short study can identify early appetite suppression but may miss a later pattern in which subjective effects diminish while calorie intake remains lower.

Third, the results may influence how companies describe treatment persistence. It is scientifically stronger to say that measured calorie intake remained lower through week 60 than to claim that participants experienced continuously intense appetite suppression. The first statement matches the trial; the second goes beyond it.

Finally, the study reinforces the importance of distinguishing efficacy from mechanism. The trial observed a behavioral pattern associated with semaglutide treatment. It did not prove that one particular brain circuit or neurotransmitter pathway caused the result.

Regulatory & Compliance Notes

Semaglutide is an approved prescription medicine in specific products and indications, but this study does not expand an approved indication. It is a clinical research publication, not a recommendation for off-label use, self-directed treatment, or use of unapproved semaglutide products.

The trial used semaglutide 2.4 mg under a controlled research protocol. Reporting the study’s dose and timing is necessary to describe the research accurately, but those details should not be interpreted as individualized dosing instructions.

As with any clinical study, the findings apply most directly to the population enrolled and the methods used. They do not establish that compounded, counterfeit, mislabeled, or research-use-only products produce the same effects. Product identity, manufacturing quality, concentration, sterility, and pharmacologic exposure can differ substantially outside a controlled trial.

Readers who want to understand how to assess clinical evidence can use GLP1Place’s guide on how to read a GLP-1 clinical trial. The central compliance point is straightforward: a peer-reviewed trial describes evidence; it does not authorize a product, seller, or personal treatment plan.

Market Forecast

The obesity-drug market is moving toward increasingly detailed claims about appetite, food preference, reward, and metabolic behavior. This study may strengthen interest in medicines that demonstrate not only weight reduction but also durable changes in eating patterns.

However, the commercial relevance of the findings will depend on replication. A 120-person trial is informative but not definitive. Larger studies could test whether the same separation between subjective appetite and measured calorie intake occurs across different ages, sexes, baseline body weights, diabetes status, treatment histories, and cultural eating environments.

Future products may also be compared using standardized meal tests, ecological momentary assessments, food-choice tasks, wearable data, and longer-term maintenance periods. Those tools could help determine whether reduced intake reflects smaller meals, fewer eating episodes, reduced snacking, lower preference for energy-dense foods, or a combination of factors.

The likely research direction is therefore not simply “stronger appetite suppression.” It is more nuanced: medicines may be differentiated by how they influence hunger, satiety, food reward, cravings, gastrointestinal tolerability, lean mass, and the ability to sustain lower energy intake after weight loss.

Researcher Takeaways

• The strongest durable signal was measured energy intake. Semaglutide-treated participants consumed fewer calories than placebo participants at weeks 20, 40, and 60.
• Subjective appetite changes were time-dependent. Hunger, food preoccupation, and post-meal appetite suppression were most evident earlier in the study.
• Food reward was reduced at weeks 20 and 40. The trial did not establish a statistically significant late effect at week 60 for every reward-related measure.
• The study supports a multi-factor model. Semaglutide’s long-term effects cannot be reduced to one appetite sensation or one neural mechanism.
• The sample size limits certainty. Replication in larger and more diverse populations is needed.
• Behavioral endpoints deserve more attention. Weight change alone may not capture how anti-obesity medicines alter eating patterns.

Consumer Awareness Notes

People researching semaglutide often look for a simple answer to whether the medicine will eliminate hunger or cravings. The trial does not support that expectation. It shows an average pattern in a defined research population, not a guaranteed experience for every user.

Some participants may notice strong early appetite changes. Others may notice smaller portions, fewer food thoughts, or altered food preferences without describing themselves as less hungry. Still others may experience gastrointestinal effects that influence intake but do not represent the same behavioral mechanism.

The results also do not justify using semaglutide obtained outside a licensed medical and pharmacy system. Unapproved products may have uncertain identity, concentration, sterility, and storage history. A controlled trial’s results cannot be transferred automatically to a product that was not tested in that trial.

Anyone using an approved prescription medicine should discuss persistent symptoms, inadequate nutrition, excessive weight loss, or concerns about eating behavior with a qualified healthcare professional. This article is educational and does not provide individualized medical advice.

Frequently Asked Questions

What did the 60-week semaglutide food reward study find?

The randomized trial found that participants receiving semaglutide 2.4 mg consumed significantly fewer calories than placebo participants at weeks 20, 40, and 60. Some subjective appetite and food-reward differences were strongest at week 20 and became less distinct later.

Did semaglutide reduce food cravings throughout the entire study?

Not every subjective measure remained significantly different through week 60. Semaglutide reduced hunger, food preoccupation, and food-reward responsiveness earlier in the study, but several appetite outcomes no longer differed significantly from placebo at weeks 40 and 60.

How many people were included in the semaglutide trial?

The study randomized 120 adults with overweight or obesity in a 3:2 allocation to semaglutide 2.4 mg or placebo. The researchers performed laboratory assessments at baseline and weeks 20, 40, and 60.

What does the study suggest about semaglutide and weight maintenance?

The findings suggest that sustained reductions in measured energy intake may help maintain weight loss even when the initial subjective feeling of appetite suppression becomes less prominent. The study did not prove that calorie reduction is the only mechanism involved.

Does this trial prove that semaglutide changes the brain’s reward system?

No. The study measured food-reward responsiveness using behavioral and questionnaire-based tools, including the Power of Food Scale. It supports a change in eating behavior but does not by itself prove a specific neural mechanism.

Was this a clinical trial or an observational study?